Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hi (anti-CD20) vs rituximab with CHOP in previously untreated DLBCL
CTR20160466Phase 2Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Sep 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of insulin icodec in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started Sep 2016; status: completed.
02
Drugs
insulin icodec
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20160466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160466.